前立腺肥大症に対する経口アンチアンドロゲン剤プロスタール錠25(酢酸クロルマジノン25mg錠)の臨床効果の検討 - 第1報 -

Abstract

Two tablets a day (50 mg/day as Chlormadinone acetate) of Prostal") Tablet 25, an oral anti androgen preparation, were administered for 16 weeks, to 22 outpatients examined at our Department, and who were diagnosed as having benign prostatic hyperplasia. The improvement rate in subjective symptoms was 95.2% for delay of starting time, 66.7% for prolonged voiding time, 95.5% for straining upon urination, 70.0% for forceless stream, and 77.8% for sense of residual urine. Improvement of all of these symptoms were observed in 9 of the 22 cases. The improvement rate in the objective findings, was 47.1% for diurnal thamuria, 29.4% for nocturnal thamuria, and 77.8% for rectal examination. Improvement of all of these items was observed in 3 cases, and improvement of one of the items was observed in 15 cases. Global assessment based on both the subjective symptoms and the objective findings, showed this drug to have an efficacy as high as 95.5 %, which strongly suggests its value in practical clinical use. There was no occurrence of a side effect, and no abnormal values were observed in the clinical laboratory examinations. Prostal® Tablet 25 was recognized to have good clinical effects and was assessed as being an extremely useful therapeutic drug in the treatment of primary hyperplasia, cases with poor risk, and prevention of post-operative recurrence. It may serve as a future therapeutic countermeasure against prostatic tumors including applications to prostatic carcinoma.